Loading...
XSHG
603351
Market cap515mUSD
Dec 05, Last price  
26.90CNY
1D
0.22%
1Q
-6.24%
IPO
-13.61%
Name

Nanjing Well Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603351 chart
P/E
24.88
P/S
2.81
EPS
1.08
Div Yield, %
1.12%
Shrs. gr., 5y
0.74%
Rev. gr., 5y
8.04%
Revenues
1.30b
+12.19%
527,598,124498,690,763558,443,860694,110,645801,451,310880,756,050736,063,7481,042,305,9151,111,010,6821,155,839,7761,296,753,389
Net income
146m
+30.50%
44,827,77260,671,29473,674,043107,432,216111,814,351128,107,850100,446,704101,370,20495,028,722112,199,192146,421,823
CFO
222m
+84.45%
74,615,18581,135,872128,181,46671,271,47463,758,147129,694,09993,304,3520108,989,026120,243,703221,793,445
Dividend
Jun 13, 20240.3 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical auxiliary materials in China. Its pharmaceutical materials include excipients for injectables and non-injectables. The company also provides synthetic base oils, such as hydraulic fluids, lubricity additives for metals, metal quenching, base fluids and lubricity additives, synthetic base for compress lubricants, synthetic base oil for gear, base oil of chain lubricants, base stock of engine oil, base stock of heat transfer oil, and base oil of grease; and other products, including painting and coating, textile chemicals, field chemicals, and low foam metal cleaners. It also exports its products to Europe, the United States, Southeast Asia, and internationally. The company was formerly known as Nanjing Well Pharmaceutical Co.,Ltd. and changed its name to Nanjing Well Pharmaceutical Group Co.,Ltd. in April 2020. The company was founded in 2000 and is based in Nanjing, China.
IPO date
Jan 30, 2019
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT